Rheumatologist Guide to Adipose Banking and the Autoimmune Research Pipeline
Rheumatologists managing lupus, rheumatoid arthritis, and related conditions encounter growing patient interest in stem cells, often framed around immune modulation. This guide gives an accurate read of the autoimmune adipose-derived pipeline, addresses how active disease and treatment affect banking considerations, and frames the patient conversation honestly for an RA or lupus patient. TLDR: Adipose-derived stem […]
Atopic Dermatitis and Adipose Stem Cells: What Patients Need to Know
Atopic dermatitis, the chronic inflammatory skin condition many people call eczema, can be stubborn, and patients whose symptoms resist standard options often go looking for what is next in research. Adipose-derived stem cells appear in that search, usually tied to terms like secretome and immune modulation. This guide explains what the research is genuinely studying, […]
Sports Medicine Physicians and Stem Cell Banking: Documentation, State Scope, and the Trial Pipeline Before July 1
Sports medicine is the specialty where the banking conversation arises most naturally. Patients are often young, healthy, and motivated to protect physical function over a long horizon, and they already understand PRP and biologic approaches, so the conceptual distance to banking is short. Two state frameworks bear directly on the specialty: Florida SB 1768 has […]
Right to Try vs. Expanded Access: The Critical Differences Every Physician Must Know
Since the federal Right to Try Act was signed in 2018, the two pathways for reaching investigational therapies outside a clinical trial, Right to Try and expanded access, have often been treated as interchangeable. They are not. They differ in legal basis, FDA involvement, IRB requirements, eligibility standards, and the protections each affords, and those […]
The Physician’s Guide to Expanded Access: How to Submit a Single-Patient IND Application
When a patient with a serious or life-threatening condition cannot enroll in a clinical trial, FDA’s expanded access framework is the pathway that can authorize use of an investigational therapy outside a trial. For cell therapies specifically, the single-patient IND is the most commonly used route, and it is also the downstream mechanism that can […]
Heart Failure and Adipose Stem Cells: The Phase II Evidence Physicians Are Watching
Heart failure is a chronic, progressive condition affecting millions of Americans, and despite guideline-directed medical therapy, a substantial share of patients remain symptomatic. That has driven investigational interest in mesenchymal stem cell therapy on the basis of paracrine cardioprotective mechanisms. The most-cited adipose-derived program, the Danish CSCC_ASC trial (NCT03092284), is a useful anchor for understanding […]
ALS and Adipose-Derived Stem Cells: The Intrathecal MSC Trial at Mayo Clinic
Amyotrophic lateral sclerosis is a fatal, rapidly progressive neurodegenerative disease, and the speed of that progression creates the most time-sensitive banking consideration in regenerative medicine. Most patients lose the functional capacity for an outpatient harvest procedure within roughly 18 to 36 months of diagnosis. Mayo Clinic’s Phase 2 trial, NCT03268603, is studying intrathecal autologous adipose-derived […]
Crohn’s Disease and Adipose-Derived Stem Cells: What the Darvadstrocel Story Tells GI Physicians
Darvadstrocel (cx601, marketed as Alofisel) was the first allogeneic adipose-derived mesenchymal stem cell therapy to receive central marketing authorization from a major regulator, when the European Commission approved it in 2018 for complex perianal fistulas in Crohn’s disease. It is also a cautionary case: the confirmatory Phase 3 trial failed in 2023, and the EU […]
Hope Biosciences and the TBI Trial: Autologous Adipose MSCs for Chronic Brain Injury (NCT05951777)
Chronic traumatic brain injury has no FDA-approved disease-modifying or regenerative therapy, leaving treatment largely supportive and rehabilitative. Hope Biosciences’ Phase 2 trial, NCT05951777, is studying the company’s autologous adipose-derived mesenchymal stem cells in chronic TBI against a saline placebo. The banking question this raises is different from the one in a rapidly progressive disease: many […]
The Mayo Clinic Multiple System Atrophy Trial: What Physicians Need to Know (NCT05167721)
Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease with no disease-modifying treatment, which makes the question of preserving future options unusually pressing for the patients and physicians who face it. Mayo Clinic’s Phase 2 trial, NCT05167721, is studying autologous adipose-derived mesenchymal stem cells administered intrathecally in MSA. What follows is what treating physicians […]